Your browser doesn't support javascript.
loading
Responsiveness and Minimal Clinically Important Difference of the Motor Function Measure in Collagen VI-Related Dystrophies and Laminin Alpha2-Related Muscular Dystrophy.
Le Goff, Laure; Meilleur, Katherine G; Norato, Gina; Rippert, Pascal; Jain, Minal; Fink, Margaret; Foley, A Reghan; Waite, Melissa; Donkervoort, Sandra; Bönnemann, Carsten G; Vuillerot, Carole.
Affiliation
  • Le Goff L; Department of Pediatric Physical Medicine and Rehabilitation, Hospices Civils de Lyon, Bron, France. Electronic address: laure.le-goff@chu-lyon.fr.
  • Meilleur KG; National Institute of Nursing Research, National Institutes of Health, Bethesda, MD; Neuromuscular and Neurogenetic Disorders of Childhood Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD.
  • Norato G; Office of Biostatistics, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD.
  • Rippert P; Public Health Center, Research and Clinical Epidemiology Department, Hospices Civils de Lyon, Lyon, France.
  • Jain M; Mark O. Hatfield Clinical Research Center, National Institutes of Health, Bethesda, MD.
  • Fink M; Neuromuscular and Neurogenetic Disorders of Childhood Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD.
  • Foley AR; Neuromuscular and Neurogenetic Disorders of Childhood Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD.
  • Waite M; Mark O. Hatfield Clinical Research Center, National Institutes of Health, Bethesda, MD.
  • Donkervoort S; Neuromuscular and Neurogenetic Disorders of Childhood Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD.
  • Bönnemann CG; Neuromuscular and Neurogenetic Disorders of Childhood Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD.
  • Vuillerot C; Department of Pediatric Physical Medicine and Rehabilitation, Hospices Civils de Lyon, Bron, France; Neuromuscular and Neurogenetic Disorders of Childhood Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD; Neuromyogen Institute, CNRS UMR 53
Arch Phys Med Rehabil ; 102(4): 604-610, 2021 04.
Article in En | MEDLINE | ID: mdl-33166523
ABSTRACT

OBJECTIVES:

To investigate the responsiveness of the motor function measure (MFM) and determine the minimal clinically important difference (MCID) in individuals with 2 common types of congenital muscular dystrophy (CMD).

DESIGN:

Observational, prospective, single center, cohort study.

SETTING:

National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH).

PARTICIPANTS:

Individuals (N=44) with collagen VI-related dystrophies (COL6-RD, n=23) and 21 individuals laminin alpha2-related muscular dystrophy (LAMA2-RD, n=21) enrolled in a 4-year longitudinal natural history study.

INTERVENTIONS:

Not applicable. MAIN OUTCOME

MEASURES:

Responsiveness of the MFM-32 and the Rasch-scaled MFM-25 and the MCID of the MFM-32 determined from a patient-reported anchor with 2 different methods, within-patient and between-patient.

RESULTS:

The original MFM-32 and Rasch-scaled MFM-25 performed similarly overall in both the COL6-RD and LAMA2-RD populations, with all subscores (D1, standing and transfers; D2, axial and proximal; D3, distal) showing a significant decrease over time, except MFM D1 and D3 for LAMA2-RD. The MFM D1 subscore was the most sensitive to change for ambulant individuals, whereas the MFM D2 subscore was the most sensitive to change for nonambulant individuals. The MCID for the MFM-32 total score was calculated as 2.5 and 3.9 percentage points according to 2 different methods.

CONCLUSIONS:

The MFM showed strong responsiveness in individuals with LAMA2-RD and COL6-RD. Because a floor effect was identified more prominently with the Rasch-Scaled MFM-25, the use of the original MFM-32 as a quantitative variable with the assumption of scale linearity appears to be a good compromise. When designing clinical trials in congenital muscular dystrophies, the use of MCID for MFM should be considered to determine if a given intervention effects show not only a statistically significant change but also a clinically meaningful change.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Disability Evaluation / Minimal Clinically Important Difference / Motor Activity / Muscular Dystrophies Type of study: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adolescent / Adult / Child / Child, preschool / Female / Humans / Male Language: En Journal: Arch Phys Med Rehabil Year: 2021 Type: Article

Full text: 1 Database: MEDLINE Main subject: Disability Evaluation / Minimal Clinically Important Difference / Motor Activity / Muscular Dystrophies Type of study: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adolescent / Adult / Child / Child, preschool / Female / Humans / Male Language: En Journal: Arch Phys Med Rehabil Year: 2021 Type: Article